Read by QxMD icon Read


Matias-Ferrán Escobedo, Luis García-Consuegra, Silvia Gay, Lorena Álvarez, Sonsoles Olay, Giuliano Ascani, Luis Junquera
Background: This study aims to evaluate the influence of changes in the teaching contents on medication-related osteonecrosis of the jaw may have on the knowledge and the capacity for practical case resolution about this pathology. Material and Methods: A cross-sectional descriptive study was conducted through a survey divided into four sections: degree of means of knowledge acquisition, habitual practice and ability to solve clinical cases. The total number of respondents (n = 225) was divided into two groups: Group A (Year 2015-2016) and Group B (Year 2016-2017)...
December 2017: Journal of Clinical and Experimental Dentistry
Yifan Zhang, Xiaoyan Chen, Yunbiao Tang, Youming Lu, Lixia Guo, Dafang Zhong
PURPOSE: The aim of this study was to evaluate the bioequivalence of a generic product 70 mg alendronate sodium tablets with the reference product Fosamax(®) 70 mg tablet. MATERIALS AND METHODS: A single-center, open-label, randomized, three-period, three-sequence, reference-replicated crossover study was performed in 36 healthy Chinese male volunteers under fasting conditions. In each study period, the volunteers received a single oral dose of the generic or reference product (70 mg)...
2017: Drug Design, Development and Therapy
Aasis Unnanuntana, Atthakorn Jarusriwanna, Panupan Songcharoen
INTRODUCTION: Although the same efficacy and tolerability are anticipated due to both drugs containing the same active ingredients, comparative studies between brand and generic alendronate are limited. Accordingly, the objective of this study was to compare efficacy and safety between brand alendronate and a recently introduced generic alendronate drug. METHODS: A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period...
2017: PloS One
Rita L Hui, Annette L Adams, Fang Niu, Bruce Ettinger, David K Yi, Malini Chandra, Joan C Lo
BACKGROUND: Examining drug exposure is essential to pharmacovigilance, especially for bisphosphonate (BP) therapy. OBJECTIVE: To examine differences in 4 measures of oral BP exposure: treatment discontinuation, adherence, persistence, and nonpersistence. METHODS: Among women aged ≥ 50 years who initiated oral BP therapy during 2002-2007 with at least 3 years of health plan membership follow-up, discontinuation was defined by evidence of no further treatment during the study observation period...
April 2017: Journal of Managed Care & Specialty Pharmacy
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby, Neil Gittoes
BACKGROUND: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax® and Fosamax® Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel® and Actonel Once a Week® , Warner Chilcott UK Ltd), ibandronic acid (Bonviva® , Roche Products Ltd) and zoledronic acid (Aclasta® , Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their cost-effectiveness at varying levels of fracture risk...
October 2016: Health Technology Assessment: HTA
Kevin W McConeghy, Melinda M Soriano, Larry H Danziger
BACKGROUND: Studies have shown associations between Clostridium difficile infection (CDI) and non-antimicrobial medications including proton pump inhibitors, osteoporosis medications, and antidepressants. OBJECTIVES: Our primary objective was to evaluate oral bisphosphonates and reported CDI adverse drug reactions in the United States using the Food and Drug Administration Adverse Event Reporting System data (FAERS). METHODS: We performed a disproportionality analysis evaluating the proportion of reports with bisphosphonates and CDI compared with other adverse drug reactions in the database...
October 2016: Pharmacotherapy
Jen-Sheng Chen, Po-Ming Chen, Chun-Yi Lin, Rong-Fu Chen, Pei-Yuan Lee
The epidemiological hip fracture leads to a high death rate in the elderly with osteoporosis worldwide. However, the appropriate surgical styles or anti-osteoporotic therapy could prevent these patients with hip fractures from suffering refracture, but the efficacy of such treatment remains elusive for first hip fractured patients. Our retrospective analysis was conducted on 508 hip fracture patients who were enrolled from Show Chwan Memorial Hospital from January 2005 through December 2011 and followed up until the end of 2012...
May 2016: Pakistan Journal of Pharmaceutical Sciences
Guangming Chen, Chaopeng Wang, Jiefang Wang, Sujuan Yin, Han Gao, L U Xiang, Hengrui Liu, Yinquan Xiong, Panpan Wang, Xiaofeng Zhu, L I Yang, Ronghua Zhang
Icariin (ICA), the main active flavonoid glucoside isolated from Herba Epimedii, has been shown to prevent postmenopausal bone loss in vitro. However, the mechanisms by which ICA prevents bone loss in vivo remain poorly understood. In the present study, the effect of ICA in an ovariectomized (OVX) rat model of osteoporosis was evaluated. Sprague-Dawley rats were divided into sham-operated and OVX groups. The OVX rats were randomly divided into five groups: OVX group (water only), Fosamax (positive) group (5...
July 2016: Experimental and Therapeutic Medicine
Smita Jha, Zhong Wang, Nicholas Laucis, Timothy Bhattacharyya
Bisphosphonates are effective for the treatment of osteoporosis despite recent reports of safety concerns such as atypical femur fracture. We conducted an ecological analysis of relevant media reports, oral bisphosphonate use, and fracture outcomes in the United States. Trends in media reports and public interest of bisphosphonates were quantified using data from Google Trends. Data from the Medical Expenditure Panel Survey (MEPS) and the National Inpatient Sample (NIS) were used to estimate the trends in oral bisphosphonate use among patients aged 55 years and older and hospitalizations for intertrochanteric and subtrochanteric fractures, respectively...
December 2015: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Shin-Yu Chen, Hui-Tzu Yu, Ju-Po Kao, Chung-Chun Yang, Shen-Shih Chiang, Darya O Mishchuk, Jeng-Leun Mau, Carolyn M Slupsky
Alendronate sodium (Fosamax) is most widely used for the prevention and treatment of osteoporosis. It is a type of anti-resorptive agent that reduces the risk of fractures by changing bone turnover and bone mineral density. We investigated the effect of Fosamax on a mouse model of osteoporosis. Twenty-seven female C57BL/6JNarl mice were divided into three groups: sham, ovariectomized (OVX) and OVX + Fosamax (Fosamax). After 23 weeks, bone density of femurs was analyzed using microcomputed tomography (micro-CT), and serum was analyzed for osteoblast and osteoclast activity, as well as metabolites using nuclear magnetic resonance (NMR) spectroscopy...
2014: PloS One
Fahd Alsalleeh, Jeffery Keippel, Lyde Adams, Bruce Bavitz
INTRODUCTION: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-known complication caused by amino-bisphosphonate therapy. We document one case of BRONJ associated with oral administration of methotrexate, a known immunosuppressive drug used to treat rheumatoid arthritis. METHODS: A 66-year-old woman was referred for evaluation and endodontic surgery of recently re-treated tooth 13. Tooth 14 was extracted 3 months prior, and the extraction site had not completely healed...
September 2014: Journal of Endodontics
Pouran Famili, Jennifer M Zavoral
The aim of this case-control study (n = 30) was to evaluate the effects of osteoporosis/osteopenia on the success of dental implants. Twenty healthy females ages 50-80 with confirmed osteoporosis or osteopenia, and 10 age- and gender-matched subjects with normal bone density (controls) received dental implants. Dual-energy X-ray absorptiometry (DXA) scans at 5 standard sites (total body, hip, spine [lateral and anterior-posterior] and radius) were measured at baseline and 24 months. Periapical and panoramic radiographs were taken at baseline before implant placement; 1 periapical radiograph was taken immediately after placement of the dental implant...
October 2015: Journal of Oral Implantology
Vicki C Petropoulos, Thomas J Balshi, Glenn J Wolfinger, Stephen F Balshi
No abstract text is available yet for this article.
February 2016: Journal of Oral Implantology
Giorgio L Colombo, Carlo Maurizio Montecucco
INTRODUCTION: The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. PATIENTS AND METHODS: Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ®) in real clinical practice...
September 2013: Clinical Cases in Mineral and Bone Metabolism
Jane Burch, Stephen Rice, Huiqin Yang, Aileen Neilson, Lisa Stirk, Roger Francis, Paul Holloway, Peter Selby, Dawn Craig
BACKGROUND: There is currently no standard practice for the monitoring of patients receiving treatment for osteoporosis. Repeated dual-energy X-ray absorptiometry (DXA) is commonly used for monitoring treatment response, but it has its limitations. Bone turnover markers have advantages over DXA as they are non-invasive, relatively cheap and can detect changes in bone turnover rates earlier. However, they do have disadvantages, particularly high within- and between-patient variability...
February 2014: Health Technology Assessment: HTA
Soo Yong Kang, Ji-Hoon Baek, Bun Jung Kang, Min Kyu Kim, Han-Jun Lee
A number of reports regarding atypical fractures of the femur have raised questions concerning the possible correlation between long-term bisphosphonate treatment and the occurrence of insufficiency fractures in the proximal femur. However, clinically, it is often confused whether is it a fatigue fracture because of implant induced stress concentration or a bisphosphonate-related atypical fracture, especially in a patient with a subtrochanteric fracture who receive bisphosphonate therapy after open reduction and internal fixation, such as dynamic hip screw (DHS) fixation for previous ipsilateral femoral neck or intertrochanteric fracture...
November 2012: Journal of Bone Metabolism
Diane K Wysowski, Patty Greene
Bisphosphonates have been widely prescribed to postmenopausal women for treatment and prevention of osteoporosis. Given a background of reports of recent safety problems, questions about optimal duration of use, and the patent expiration of Fosamax in February 2008, we accessed data from pharmaceutical marketing research databases to describe trends in dispensed prescriptions and sales of oral bisphosphonates, characteristics of patients and prescribers, and sales of intravenous bisphosphonates for osteoporosis treatment...
December 2013: Bone
Ida Iren Eriksen, Hans Olav Melberg, Berit Bringedal
The objectives of this study are to measure physicians' knowledge of the prices of pharmaceuticals, and investigate whether there are differences in knowledge of prices between groups of physicians. This article reports on a survey study of physicians' knowledge of the prices of pharmaceuticals conducted on a representative sample of Norwegian physicians in the autumn of 2010. The importance of physicians' knowledge of costs derives from their influence on total spending and allocation of limited health-care resources...
2013: PloS One
Shih-Hsun Chen, Sheng-Wei Lin, Shen-Rong Lin, Po-Huang Liang, Jinn-Moon Yang
Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS). Current bisphosphonate drugs (e.g., Fosamax and Zometa) are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease, and tumor-induced osteolysis, but they are often less potent in blood and soft-tissue due to their phosphate moieties. The discovery of nonbisphosphonate inhibitors of FPPS and/or GGPPS for the treatment of bone diseases and cancers is, therefore, a current goal...
September 23, 2013: Journal of Chemical Information and Modeling
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"